1
|
Tan CF, Wang J, Zhong XR, Dai ZL, Xiang ZZ, Zeng YY, Wei XY, Xu NY, Liu L. Is postmastectomy radiotherapy necessary for breast cancer patients with clinically node-positive downstaging to ypN0 after neoadjuvant chemotherapy? Breast Cancer Res Treat 2024:10.1007/s10549-024-07249-2. [PMID: 38616207 DOI: 10.1007/s10549-024-07249-2] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/01/2023] [Accepted: 01/04/2024] [Indexed: 04/16/2024]
Abstract
PURPOSE The significance of postmastectomy radiotherapy (PMRT) in breast cancer patients who initially have clinically node-positive (cN +) status but achieve downstaging to ypN0 following neoadjuvant chemotherapy (NAC) remains uncertain. This study aims to assess the impact of PMRT in this patient subset. METHODS Patients were enrolled from West China Hospital, Sichuan University from 2008 to 2019. Overall survival (OS), Locoregional recurrence-free survival (LRFS), distant metastasis-free survival (DMFS), and breast cancer-specific survival (BCSS) were estimated using the Kaplan-Meier method and assessed with the log-rank test. The impact of PMRT was further analyzed by the Cox proportional hazards model. Propensity score matching (PSM) was performed to reduce the selection bias. RESULTS Of the 333 eligible patients, 189 (56.8%) received PMRT, and 144 (43.2%) did not. At a median follow-up period of 71 months, the five-year LRFS, DMFS, BCSS, and OS rates were 99.1%, 93.4%, 96.4%, and 94.3% for the entire cohort, respectively. Additionally, the 5-year LRFS, DMFS, BCSS, and OS rates were 98.9%, 93.8%, 96.7%, and 94.5% with PMRT and 99.2%, 91.3%, 94.9%, and 92.0% without PMRT, respectively (all p-values not statistically significant). After multivariate analysis, PMRT was not a significant risk factor for any of the endpoints. When further stratified by stage, PMRT did not show any survival benefit for patients with stage II-III diseases. CONCLUSION In the context of comprehensive treatments, PMRT might be exempted in ypN0 breast cancer patients. Further large-scale, randomized controlled studies are required to investigate the significance of PMRT in this patient subset.
Collapse
Affiliation(s)
- Chen-Feng Tan
- Division of Head & Neck Tumor Multimodality Treatment, Cancer Center, West China Hospital, Sichuan University, Chengdu, Sichuan, People's Republic of China
| | - Jun Wang
- Division of Head & Neck Tumor Multimodality Treatment, Cancer Center, West China Hospital, Sichuan University, Chengdu, Sichuan, People's Republic of China
| | - Xiao-Rong Zhong
- Breast Center, Cancer Center, West China Hospital, Sichuan University, Chengdu, Sichuan, People's Republic of China
| | - Ze-Lei Dai
- Division of Head & Neck Tumor Multimodality Treatment, Cancer Center, West China Hospital, Sichuan University, Chengdu, Sichuan, People's Republic of China
| | - Zhong-Zheng Xiang
- Division of Head & Neck Tumor Multimodality Treatment, Cancer Center, West China Hospital, Sichuan University, Chengdu, Sichuan, People's Republic of China
| | - Yuan-Yuan Zeng
- Division of Head & Neck Tumor Multimodality Treatment, Cancer Center, West China Hospital, Sichuan University, Chengdu, Sichuan, People's Republic of China
| | - Xiao-Yuan Wei
- Division of Head & Neck Tumor Multimodality Treatment, Cancer Center, West China Hospital, Sichuan University, Chengdu, Sichuan, People's Republic of China
| | - Ning-Yue Xu
- Division of Head & Neck Tumor Multimodality Treatment, Cancer Center, West China Hospital, Sichuan University, Chengdu, Sichuan, People's Republic of China
| | - Lei Liu
- Division of Head & Neck Tumor Multimodality Treatment, Cancer Center, West China Hospital, Sichuan University, Chengdu, Sichuan, People's Republic of China.
| |
Collapse
|
2
|
Wang J, Luo T, Xiang ZZ, He MM, Zeng YY, Yang T, Wei XY, Yu S, Dai ZL, Xu NY, Tan CF, Liu L. Survival and Trends in Annualized Hazard Function by Age at Diagnosis Among Chinese Breast Cancer Patients Aged ≤40 Years: Case Analysis Study. JMIR Public Health Surveill 2023; 9:e47110. [PMID: 37463020 PMCID: PMC10394600 DOI: 10.2196/47110] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/10/2023] [Revised: 04/19/2023] [Accepted: 06/15/2023] [Indexed: 07/21/2023] Open
Abstract
BACKGROUND Young breast cancer patients are more likely to develop aggressive tumor characteristics and a worse prognosis than older women, and different races and ethnicities have distinct epidemiologies and prognoses. However, few studies have evaluated the clinical biological features and relapse patterns in different age strata of young women in Asia. OBJECTIVE We aimed to explore survival differences and the hazard function in young Chinese patients with breast cancer (BC) by age. METHODS The patients were enrolled from West China Hospital, Sichuan University. The chi-squared test, a Kaplan-Meier analysis, a log-rank test, a Cox multivariate hazards regression model, and a hazard function were applied for data analysis. Locoregional recurrence-free survival (LRFS), distant metastasis-free survival (DMFS), breast cancer-specific survival (BCSS), and overall survival (OS) were defined as end points. RESULTS We included 1928 young BC patients diagnosed between 2008 and 2019. Patients aged 18 to 25, 26 to 30, 31 to 35, and 36 to 40 years accounted for 2.7% (n=53), 11.8% (n=228), 27.7% (n=535), and 57.7% (n=1112) of the patients, respectively. The diagnosis of young BC significantly increased from 2008 to 2019. Five-year LRFS, DMFS, BCSS, and OS for the entire population were 98.3%, 93.4%, 94.4%, and 94%, respectively. Patients aged 18 to 25 years had significantly poorer 5-year LRFS (P<.001), 5-year DMFS (P<.001), 5-year BCSS (P=.04), and 5-year OS (P=.04) than those aged 31 to 35, 26 to 30, and 36 to 40 years. The hazard curves for recurrence and metastasis for the whole cohort continuously increased over the years, while the BC mortality risk peaked at 2 to 3 years and then slowly decreased. When stratified by age, the annualized hazard function for recurrence, metastasis, and BC mortality in different age strata showed significantly different trends, especially for BC mortality. CONCLUSIONS The annual diagnosis of young BC seemed to increase in Chinese patients, and the distinct age strata of young BC patients did not differ in survival outcome or failure pattern. Our results might provide strategies for personalized management of young BC.
Collapse
Affiliation(s)
- Jun Wang
- Department of Head and Neck Oncology, West China Hospital, Sichuan University, Chengdu, China
| | - Ting Luo
- Breast Disease Center, Cancer Center, West China Hospital, Sichuan University, Chengdu, China
| | - Zhong-Zheng Xiang
- Department of Head and Neck Oncology, West China Hospital, Sichuan University, Chengdu, China
| | - Ming-Min He
- Department of Head and Neck Oncology, West China Hospital, Sichuan University, Chengdu, China
| | - Yuan-Yuan Zeng
- Department of Head and Neck Oncology, West China Hospital, Sichuan University, Chengdu, China
| | - Tian Yang
- Department of Head and Neck Oncology, West China Hospital, Sichuan University, Chengdu, China
| | - Xiao-Yuan Wei
- Department of Head and Neck Oncology, West China Hospital, Sichuan University, Chengdu, China
| | - Siting Yu
- Department of Head and Neck Oncology, West China Hospital, Sichuan University, Chengdu, China
| | - Ze-Lei Dai
- Department of Head and Neck Oncology, West China Hospital, Sichuan University, Chengdu, China
| | - Ning-Yue Xu
- Department of Head and Neck Oncology, West China Hospital, Sichuan University, Chengdu, China
| | - Chen-Feng Tan
- Department of Head and Neck Oncology, West China Hospital, Sichuan University, Chengdu, China
| | - Lei Liu
- Department of Head and Neck Oncology, West China Hospital, Sichuan University, Chengdu, China
| |
Collapse
|
3
|
He T, Yan RN, Chen HY, Zeng YY, Xiang ZZ, Liu F, Shao BF, Ma JC, Wang XR, Liu L. Comparing the 7th and 8th editions of UICC/AJCC staging system for nasopharyngeal carcinoma in the IMRT era. BMC Cancer 2021; 21:327. [PMID: 33785010 PMCID: PMC8011200 DOI: 10.1186/s12885-021-08036-8] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/13/2020] [Accepted: 03/09/2021] [Indexed: 02/08/2023] Open
Abstract
Background To compare the prognostic value of 7th and 8th editions of the Union for International Cancer Control/American Joint Committee on Cancer (UICC/AJCC) staging system for patients with nonmetastatic nasopharyngeal carcinoma (NPC) treated with intensity-modulated radiotherapy and simultaneous integrated boost– intensity-modulated radiation therapy (SIB-IMRT). Methods Patients with NPC (n = 300) who received SIB-IMRT were included. Survival by T-classification, N-classification, and stage group of each staging system was assessed. Results For T-classification, nonsignificant difference was observed between T1 and T3 and between T2 and T3 disease (P = 0.066 and 0.106, respectively) for overall survival (OS) in the 7th staging system, whereas all these differences were significant in the 8th staging system (all P < 0.05). The survival curves for disease-free survival (DFS) and locoregional recurrence-free survival (LRRFS) in both staging systems were similar, except for the comparison of T2 and T4 disease for LRRFS (P = 0.070 for 7th edition; P = 0.011 for 8th edition). For N-classification, significant differences were observed between N2 and N3 diseases after revision (P = 0.046 and P = 0.043 for OS and DFS, respectively). For staging system, no significant difference was observed between IVA and IVB of 7th edition. Conclusion The 8th AJCC staging system appeared to have superior prognosis value in the SIB-IMRT era compared with the 7th edition. Supplementary Information The online version contains supplementary material available at 10.1186/s12885-021-08036-8.
Collapse
Affiliation(s)
- Tao He
- Department of Head and Neck Oncology, Cancer Center, State Key Laboratory of Biotherapy, and the Department of Radiation Oncology, West China Hospital, Sichuan University, No. 37 Guo Xue Alley, Chengdu, Sichuan, PR China.,Department of Radiation Oncology, Cancer Center, The Sixth Floor Of The Third Inpatient Building Of West China Hospital Of Sichuan, West China Hospital, Sichuan University, Chengdu, Sichuan, PR China
| | - Ruo-Nan Yan
- Department of Head and Neck Oncology, Cancer Center, State Key Laboratory of Biotherapy, and the Department of Radiation Oncology, West China Hospital, Sichuan University, No. 37 Guo Xue Alley, Chengdu, Sichuan, PR China.,Department of Radiation Oncology, Cancer Center, The Sixth Floor Of The Third Inpatient Building Of West China Hospital Of Sichuan, West China Hospital, Sichuan University, Chengdu, Sichuan, PR China
| | - Hua-Ying Chen
- Department of Head and Neck Oncology, Cancer Center, State Key Laboratory of Biotherapy, and the Department of Radiation Oncology, West China Hospital, Sichuan University, No. 37 Guo Xue Alley, Chengdu, Sichuan, PR China
| | - Yuan-Yuan Zeng
- Department of Head and Neck Oncology, Cancer Center, State Key Laboratory of Biotherapy, and the Department of Radiation Oncology, West China Hospital, Sichuan University, No. 37 Guo Xue Alley, Chengdu, Sichuan, PR China.,Department of Radiation Oncology, Cancer Center, The Sixth Floor Of The Third Inpatient Building Of West China Hospital Of Sichuan, West China Hospital, Sichuan University, Chengdu, Sichuan, PR China
| | - Zhong-Zheng Xiang
- Department of Head and Neck Oncology, Cancer Center, State Key Laboratory of Biotherapy, and the Department of Radiation Oncology, West China Hospital, Sichuan University, No. 37 Guo Xue Alley, Chengdu, Sichuan, PR China.,Department of Radiation Oncology, Cancer Center, The Sixth Floor Of The Third Inpatient Building Of West China Hospital Of Sichuan, West China Hospital, Sichuan University, Chengdu, Sichuan, PR China
| | - Fang Liu
- Department of Head and Neck Oncology, Cancer Center, State Key Laboratory of Biotherapy, and the Department of Radiation Oncology, West China Hospital, Sichuan University, No. 37 Guo Xue Alley, Chengdu, Sichuan, PR China.,Department of Radiation Oncology, Cancer Center, The Sixth Floor Of The Third Inpatient Building Of West China Hospital Of Sichuan, West China Hospital, Sichuan University, Chengdu, Sichuan, PR China
| | - Bian-Fei Shao
- Department of Head and Neck Oncology, Cancer Center, State Key Laboratory of Biotherapy, and the Department of Radiation Oncology, West China Hospital, Sichuan University, No. 37 Guo Xue Alley, Chengdu, Sichuan, PR China.,Department of Radiation Oncology, Cancer Center, The Sixth Floor Of The Third Inpatient Building Of West China Hospital Of Sichuan, West China Hospital, Sichuan University, Chengdu, Sichuan, PR China
| | - Jia-Chun Ma
- Department of Head and Neck Oncology, Cancer Center, State Key Laboratory of Biotherapy, and the Department of Radiation Oncology, West China Hospital, Sichuan University, No. 37 Guo Xue Alley, Chengdu, Sichuan, PR China.,Department of Radiation Oncology, Cancer Center, The Sixth Floor Of The Third Inpatient Building Of West China Hospital Of Sichuan, West China Hospital, Sichuan University, Chengdu, Sichuan, PR China
| | - Xi-Ran Wang
- Department of Head and Neck Oncology, Cancer Center, State Key Laboratory of Biotherapy, and the Department of Radiation Oncology, West China Hospital, Sichuan University, No. 37 Guo Xue Alley, Chengdu, Sichuan, PR China.,Department of Radiation Oncology, Cancer Center, The Sixth Floor Of The Third Inpatient Building Of West China Hospital Of Sichuan, West China Hospital, Sichuan University, Chengdu, Sichuan, PR China
| | - Lei Liu
- Department of Head and Neck Oncology, Cancer Center, State Key Laboratory of Biotherapy, and the Department of Radiation Oncology, West China Hospital, Sichuan University, No. 37 Guo Xue Alley, Chengdu, Sichuan, PR China. .,Department of Radiation Oncology, Cancer Center, The Sixth Floor Of The Third Inpatient Building Of West China Hospital Of Sichuan, West China Hospital, Sichuan University, Chengdu, Sichuan, PR China.
| |
Collapse
|
4
|
Ma JC, Zhong XR, Luo T, Xiang ZZ, Li JY, Luo C, Yan X, He P, Tian TL, Liu F, Liu L, Zheng H. Correction to: The Effect of Postmastectomy Radiotherapy on Breast Cancer Patients After Neoadjuvant Chemotherapy by Molecular Subtype. Ann Surg Oncol 2021; 28:870. [PMID: 33638048 DOI: 10.1245/s10434-021-09771-9] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/05/2023]
Affiliation(s)
- Jia-Chun Ma
- Department of Head and Neck Oncology, Cancer Center, State Key Laboratory of Biotherapy, West China Hospital, Sichuan University, Chengdu, China
| | - Xiao-Rong Zhong
- Department of Head, Neck and Mammary Gland Oncology, Cancer Center, West China Hospital, Sichuan University, Chengdu, China
| | - Ting Luo
- Department of Head, Neck and Mammary Gland Oncology, Cancer Center, West China Hospital, Sichuan University, Chengdu, China
| | - Zhong-Zheng Xiang
- Department of Head and Neck Oncology, Cancer Center, State Key Laboratory of Biotherapy, West China Hospital, Sichuan University, Chengdu, China
| | - Jia-Yuan Li
- Department of Epidemiology and Biostatistics, West China School of Public Health, Sichuan University, Chengdu, China
| | - Chuanxu Luo
- Department of Head, Neck and Mammary Gland Oncology, Cancer Center, West China Hospital, Sichuan University, Chengdu, China
| | - Xi Yan
- Department of Head, Neck and Mammary Gland Oncology, Cancer Center, West China Hospital, Sichuan University, Chengdu, China
| | - Ping He
- Department of Head, Neck and Mammary Gland Oncology, Cancer Center, West China Hospital, Sichuan University, Chengdu, China
| | - Ting-Lun Tian
- Department of Head, Neck and Mammary Gland Oncology, Cancer Center, West China Hospital, Sichuan University, Chengdu, China
| | - Fang Liu
- Department of Head and Neck Oncology, Cancer Center, State Key Laboratory of Biotherapy, West China Hospital, Sichuan University, Chengdu, China
| | - Lei Liu
- Department of Head and Neck Oncology, Cancer Center, State Key Laboratory of Biotherapy, West China Hospital, Sichuan University, Chengdu, China.
| | - Hong Zheng
- Department of Head, Neck and Mammary Gland Oncology, Cancer Center, West China Hospital, Sichuan University, Chengdu, China
| |
Collapse
|
5
|
Ma JC, Zhong XR, Luo T, Xiang ZZ, Li JY, Luo C, Yan X, He P, Tian TL, Liu F, Liu L, Zheng H. The Effect of Postmastectomy Radiotherapy on Breast Cancer Patients After Neoadjuvant Chemotherapy by Molecular Subtype. Ann Surg Oncol 2021; 28:5084-5095. [PMID: 33580420 DOI: 10.1245/s10434-020-09523-1] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/17/2020] [Accepted: 12/08/2020] [Indexed: 02/05/2023]
Abstract
BACKGROUND The effect of postmastectomy radiotherapy (PMRT) on patient outcomes after neoadjuvant chemotherapy (NAC) remains controversial. We aimed to establish a model to identify the subsets benefiting from PMRT and to examine the effect of PMRT according to molecular subtype. PATIENTS AND METHODS We retrospectively analyzed 1118 cT1-4cN0-3M0 breast cancer patients treated with NAC and mastectomy. A nomogram predicting locoregional recurrence (LRR) was established based on 418 unirradiated patients, and X-tile analysis was performed to divide the patients into two risk groups. The effect of PMRT on LRR, distant recurrence (DR), and breast cancer mortality (BCM) was estimated for patients with different molecular subtypes in two risk groups. RESULTS A nomogram predicting LRR was developed using six factors: histologic classification, lymphovascular invasion, ypT stage, ypN stage, estrogen receptor status, and Ki-67 expression. Our study found that PMRT correlated with lower 5-year LRR, DR, and BCM rates for the high-risk group; however, no significant improvement in these endpoints was observed in the low-risk group. Among patients with high risk, subgroup analysis showed that LRR control was improved after PMRT for the human epidermal growth factor receptor 2 (HER2)-negative/hormone receptor (HR)-positive (HER2-/HR+), HER2-positive (HER2+)/HR+, and HER2-/HR-negative (HR-) subtypes, with hazard ratios of 0.113 (95% confidence [CI] 0.034-0.379; p < 0.001), 0.159 (95% CI 0.038-0.671; p = 0.017), and 0.243 (95% CI 0.088-0.676; p = 0.007), respectively, but not for the HER2+/HR- subtype (p = 0.468). CONCLUSIONS We built a nomogram showing favorable risk quantification and patient stratification. Patients in the high-risk group benefited from PMRT, but patients in the low-risk group did not. PMRT may show different benefits for each molecular subtype.
Collapse
Affiliation(s)
- Jia-Chun Ma
- Department of Head and Neck Oncology, Cancer Center, State Key Laboratory of Biotherapy, West China Hospital, Sichuan University, Chengdu, China
| | - Xiao-Rong Zhong
- Department of Head, Neck and Mammary Gland Oncology, Cancer Center, West China Hospital, Sichuan University, Chengdu, China
| | - Ting Luo
- Department of Head, Neck and Mammary Gland Oncology, Cancer Center, West China Hospital, Sichuan University, Chengdu, China
| | - Zhong-Zheng Xiang
- Department of Head and Neck Oncology, Cancer Center, State Key Laboratory of Biotherapy, West China Hospital, Sichuan University, Chengdu, China
| | - Jia-Yuan Li
- Department of Epidemiology and Biostatistics, West China School of Public Health, Sichuan University, Chengdu, China
| | - Chuanxu Luo
- Department of Head, Neck and Mammary Gland Oncology, Cancer Center, West China Hospital, Sichuan University, Chengdu, China
| | - Xi Yan
- Department of Head, Neck and Mammary Gland Oncology, Cancer Center, West China Hospital, Sichuan University, Chengdu, China
| | - Ping He
- Department of Head, Neck and Mammary Gland Oncology, Cancer Center, West China Hospital, Sichuan University, Chengdu, China
| | - Ting-Lun Tian
- Department of Head, Neck and Mammary Gland Oncology, Cancer Center, West China Hospital, Sichuan University, Chengdu, China
| | - Fang Liu
- Department of Head and Neck Oncology, Cancer Center, State Key Laboratory of Biotherapy, West China Hospital, Sichuan University, Chengdu, China
| | - Lei Liu
- Department of Head and Neck Oncology, Cancer Center, State Key Laboratory of Biotherapy, West China Hospital, Sichuan University, Chengdu, China.
| | - Hong Zheng
- Department of Head, Neck and Mammary Gland Oncology, Cancer Center, West China Hospital, Sichuan University, Chengdu, China
| |
Collapse
|
6
|
Meyer KC, Cardoni A, Xiang ZZ. Vascular endothelial growth factor in bronchoalveolar lavage from normal subjects and patients with diffuse parenchymal lung disease. J Lab Clin Med 2000; 135:332-8. [PMID: 10779049 DOI: 10.1067/mlc.2000.105618] [Citation(s) in RCA: 59] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/22/2022]
Abstract
Vascular endothelial growth factor (VEGF) is a potent angiogenic agent that is expressed by epithelial cells in the mature lung of various animal species. We hypothesized that VEGF levels in lower respiratory tract secretions may vary with age or with lung inflammation in human beings. We measured VEGF165 in bronchoalveolar lavage fluid (BALF) from normal volunteers (NVs) of varying age and from patients with cystic fibrosis (CF), sarcoidosis, or idiopathic pulmonary fibrosis (IPF). A considerable gradient in VEGF levels was found with relatively high VEGF concentrations in BALF as compared with serum VEGF. VEGF levels were 303 +/- 34 pg/mL (mean +/- SEM) in serum samples from patients with CF (N = 9) versus 122 +/- 16 pg/mL for the comparable, youngest group of NVs (P < .01). BALF VEGF concentrations were 165 +/- 17 pg/mL for CF upper lobe BALF (N = 9), 140 +/- 17 pg/mL for CF lower lobe BALF (N = 9), and 235 +/- 24 pg/mL for young adult NVs (N = 29). Serum VEGF levels did not differ significantly between NVs and patients with interstitial lung disease, but mean BALF VEGF levels declined significantly with advancing age in NVs and were significantly depressed in patients with IPF (32 +/- 6 pg/mL) as compared with all other groups, including the oldest group of NVs (134 +/- 13 pg/mL, P < .0001). We conclude that a considerable gradient in VEGF concentration exists from epithelial bronchoalveolar surface fluid to serum. Concentrations of VEGF in lower respiratory tract secretions vary with age and are significantly depressed in IPF.
Collapse
Affiliation(s)
- K C Meyer
- Department of Medicine, Clinical Sciences Center, University of Wisconsin, Madison 53792, USA
| | | | | |
Collapse
|
7
|
Abstract
Applying electrical impulse stimuli at the Jing point (St. 45) and then tapping on the skin surface along the vertical lines crossing the channel of the stomach, the line of latent propagated sensation along channel (LPSC) was determined in 51 patients at the acupuncture clinic. Of the cases examined, 98 percent were found to have positive LPSC lines which were basically coincident with the classical stomach channel. Using a low frequency skin impedance detector, the skin impedance of the entire lines of LPSC was found to be lower than its adjacent areas.
Collapse
|